

13th Annual Scientific Meeting of the Cardiorenal Forum – Programme

Updates and progress in cardiorenal medicine

Friday 5th October 2018

Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London, NW1 4RG

SESSION 1. DIABETES & CARDIORENAL DISEASE

Chair: Paul Kalra, Consultant Cardiologist (Portsmouth Hospitals NHS Trust)

09.30 Which drug for which patient?

David Strain, Clinical Senior Lecturer (University of Exeter) and Honorary Consultant (Royal Devon and Exeter Hospital)

09.55 *Discussion*

10.00 Understanding the pathogenesis of vascular disease in diabetes, hypertension and obesity – does it influence treatment?

Anthony Heagerty, Professor of Medicine and Head of Division of Cardiovascular Sciences (University of Manchester)

10.25 *Discussion*

10.30 Lipid management in vascular disease – when to consider options beyond statins

Dermot Neely, Consultant in Clinical Biochemistry and Metabolic Medicine (Newcastle upon Tyne Hospitals NHS Trust)

10.55 *Discussion*

11.00 Coffee break

SESSION 2. CARDIORENAL CLINICAL UPDATES

Chair: Catherine Wall, Consultant Nephrologist (Tallaght University Hospital, Dublin, Ireland)

11.30 The British Heart Valve Society Lecture Advances in percutaneous treatment of valvular disease in patients with cardiorenal disease

Phil MacCarthy, Professor of Interventional Cardiology (King's College London) and Consultant Cardiologist (King's College Hospital, London)

11.50 *Discussion*

11.55 The British and Irish Hypertension Society Lecture Blood pressure targets in patients with cardiorenal disease. What do the guidelines say?

Una Martin, Professor of Clinical Pharmacology (University of Birmingham)

12.15 *Discussion*

12.20 British Heart Foundation Lecture Alternative pathways to immunosuppression

Federica Marelli-Berg, British Heart Foundation Chair of Cardiovascular Immunology (William Harvey Research Institute, Barts and The London School of Medicine and Dentistry)

12.40 *Discussion*

12.45 Lunch break

SESSION 3. CLINICAL TRIAL UPDATE

Chairs: Abhishek Joshi, President of the BJCA and Matthew Graham-Browne, Chair of the UK and Ireland RA Nephrology SpR Club

13.55 Cardiology trials reviewed

Lisa Anderson, Heart Failure Consultant and Head of Clinical Governance and Audit Cardiology Clinical Academic Group (St. George's University Hospitals NHS Foundation Trust, London)

14.15 *Discussion*

14.20 Nephrology trial network in the UK – does it work?

Philip Kalra, Professor of Renal Medicine (University of Manchester) and Consultant Nephrologist (Salford Royal NHS Foundation Trust)

14.40 *Discussion*

SESSION 4. IMPROVING PATIENT CARE – EXAMPLES OF COLLABORATIVE WORKING BETWEEN CARDIOLOGISTS AND NEPHROLOGISTS

Chair: David Lappin, Consultant Nephrologist (Galway University Hospitals, Ireland)

14.45 How to manage deteriorating renal function in patients with heart failure on RAAS blockade

Charles Tomson, Consultant Nephrologist (Freeman Hospital, Newcastle upon Tyne)

15.05 *Discussion*

15.10 Sudden cardiac death in end stage renal disease

Paul Roberts, Consultant Cardiologist (University Hospital Southampton NHS Trust)

15.30 *Discussion*

15.35 Tea break

SESSION 5. INTERACTIVE CLINICAL CASES

Chair: David Mulcahy, Consultant Cardiologist (Tallaght University Hospital, Dublin, Ireland)

15.55 Case 1. Hyperkalaemia

Paddy Mark, Clinical Reader and Honorary Consultant Nephrologist (Queen Elizabeth University Hospital, Glasgow)

16.15 Case 2. Anticoagulation and CKD

Charles Ferro, Consultant Nephrologist (University Hospitals, Birmingham)

16.35 Case 3. Iron deficiency

Paul WX Foley, Consultant Cardiologist (Great Western Hospital, Swindon)

16.55 Case 4. Atypical haemolytic uraemic syndrome

Neil Sheerin, Professor of Nephrology (Newcastle University)

17.15 Close

6 CPD credits awarded the Royal College of Physicians

Endorsed by the Renal Association, the Irish Nephrology Society and the British Society for Heart Failure.

Registration fee with lunch and refreshments: £130, £75 concessions (nurses and clinical trainees), £250 commercial organisations